A few other noteworthy comments:

- Don greatly emphasized on both the slides and verbally that the vertical dotted Standard of Care (SoC) line at 18 weeks represented the average time that enzalutamide treatment alone is efficacious before the typical patients develops resistance to the drug and the prostate cancer tumor growth or PSA progresses. Of course to arrive at this enzalutamide alone average SoC, some patients will progress earlier and others later. 

-Don showed 5 cohorts (presumably different doses). Cohorts 2, 3 and 4 are all looking really good with several patients ongoing (without progression) at week 18 to 64. The 3 rock stars in cohort 2 currently at around week 64 stand out. Cohort 5 is ongoing but too early to tell yet if effective. Cohort 1 had one patient that made it to 46 weeks (the rest progressed at 10-22 weeks).

-28 total patients on the graph for the combo trial. Of these, 6 are ongoing but haven't crossed the week 18 SoC line yet. 2 patients stopped prior to the week 18 SoC line because they withdrew consent. 3 patients stopped prior to the week 18 SoC line because of adverse event (not disease progression). So this leaves us with 17 patients to fairly evaluate as better or worse than the enzalutamide alone SoC. Of these 17, 6 progressed prior to the week 18 SoC and 11 passed the week 18 SoC. 9 of these 11 that passed the week 18 SoC are ongoing and 2 of the 11 progressed at 22 and 46 weeks. Great news!

- Don mentioned that some patients in the ZEN-3694/enzalutamide combo trial are not showing tumor progression but still have elevated PSA. So in some patients, Zenith is seeing a partial response (stabilized tumor) without PSA flatlining. The rock star cohort 2 patients that are a 64 weeks still have flatlined PSA in addition to progression free survival.

- Don had a great line during the presenation. Something to the effect of.....I like to tell the pharma companies that [developing resistance to their drugs] is not only the end of the road for treatment options for these patients but also the end of the road for drug revenue. 

BearDownAZ